[Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]
L'Institut national d'excellence en sante et en services sociaux (INESSS)
Record ID 32012000850
French
Authors' objectives:
The study's objectives were to describe PPI use, from 2007 to 2010, among adults aged 18 years or over who were covered by the Public Prescription Drug Insurance Plan and to compare this use with optimal utilization criteria in order to assess compliance with them.
Authors' recommendations:
The results of this study provide a brief overview of the practice and will give PPI prescribers food for thought regarding their prescribing habits. This reflection should mainly concern the frequent PPI treatments of 12 or more weeks' duration and the fact that there was no medical visit in 20% of new PPI users within the year following the start of treatment. The difficulty in providing a close follow-up of all patients who are not very ill probably explains the low level of compliance observed for the second and third optimal utilization criteria. Improvement in PPI use does, however, seem possible. This improvement would require a better follow up or evaluation of the treatment indication. We can even suppose that a better assessment of the treatment indication may improve use. The preferred use of generic rabeprazole might also substantially reduce the cost of PPIs for the Public Prescription Drug Insurance Plan with no loss of efficacy in most users. Further studies would be useful for determining if the key messages updated in 2009 and disseminated in June 2010 have had an effect on clinical practice in Québec in the short or medium term.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/ETMIS2012_Vol8_No5_IPP.pdf
URL for additional information:
http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/ETMIS2012_Vol8_No5_IPP_SUMMARY.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Adult
- Prescription Drugs
- Insurance, Health
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
L'Institut national d'excellence en sante et en services sociaux (INESSS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.